These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22865003)

  • 1. Clinicopathological features and molecular analysis of primary glioblastomas in Moroccan patients.
    Hilmani S; Abidi O; Benrahma H; Karkouri M; Sahraoui S; El Azhari A; Barakat A
    J Mol Neurosci; 2013 Mar; 49(3):567-73. PubMed ID: 22865003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
    Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
    Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
    Stancheva G; Goranova T; Laleva M; Kamenova M; Mitkova A; Velinov N; Poptodorov G; Mitev V; Kaneva R; Gabrovsky N
    Biomed Res Int; 2014; 2014():654727. PubMed ID: 24868540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
    Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
    Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?
    Sarmiento JM; Mukherjee D; Black KL; Fan X; Hu JL; Nuno MA; Patil CG
    J Neurol Surg A Cent Eur Neurosurg; 2016 May; 77(3):195-200. PubMed ID: 26935296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
    Takeuchi S; Wada K; Toyooka T; Shinomiya N; Shimazaki H; Nakanishi K; Nagatani K; Otani N; Osada H; Uozumi Y; Matsuo H; Nawashiro H
    Neurosurgery; 2013 Jan; 72(1):33-41; discussion 41. PubMed ID: 23096413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
    de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
    Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic glioblastoma: an evaluation of IDH1 status and prognosis.
    Sarmiento JM; Nuño M; Ortega A; Mukherjee D; Fan X; Black KL; Patil CG
    Neurosurgery; 2014 Jan; 74(1):71-5: discussion 75-6. PubMed ID: 24089051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and pathological significance of p53 gene mutation in human cerebral glioblastoma multiforme].
    Matsumoto R
    Hokkaido Igaku Zasshi; 1998 Jul; 73(4):407-17. PubMed ID: 9828926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
    Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY
    Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
    Shin JH; Lee YS; Hong YK; Kang CS
    J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
    Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
    Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.